PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21419084-10	2011	After treatment, GXK decoction and simvastatin improved the dyslipidemia by increasing the concentrations of ApoA I and HDL-C and decreasing the concentrations of TC, TAG, LDL-C, ApoB, CRP, SAA and Fbg (P<0.05).	Simvastatin	35-46	apolipoprotein A-I	Mus musculus	109-115	
21241519-5	2011	Plasma analysis by enzymatic method or ELISA showed that high-density lipoprotein-cholesterol (HDL-C) and apolipoprotein A-I (apoA-I) contents were remarkably increased by treatment with simvastatin.	Simvastatin	187-198	apolipoprotein A-I	Mus musculus	106-124	
21241519-5	2011	Plasma analysis by enzymatic method or ELISA showed that high-density lipoprotein-cholesterol (HDL-C) and apolipoprotein A-I (apoA-I) contents were remarkably increased by treatment with simvastatin.	Simvastatin	187-198	apolipoprotein A-I	Mus musculus	126-132	
21241519-7	2011	Real-time PCR detection disclosed that the expression of several transporters involved in reverse cholesterol transport, including macrophage scavenger receptor class B type I, hepatic ATP-binding cassette (ABC) transporters ABCG5, and ABCB4 were induced by simvastatin treatment, the expression of hepatic ABCA1 and apoA-I, which play roles in the maturation of HDL-C, were also elevated in simvastatin treated groups.	Simvastatin	258-269	apolipoprotein A-I	Mus musculus	317-323	
21241519-9	2011	We confirmed here for the first time simvastatin increased the expression of hepatic ABCB4 and ABCG5, which involved in secretion of cholesterol and bile acids into the bile, besides upregulated ABCA1 and apoA-I.	Simvastatin	37-48	apolipoprotein A-I	Mus musculus	205-211	
18540024-0	2008	Homocysteine modulates the effect of simvastatin on expression of ApoA-I and NF-kappaB/iNOS.	Simvastatin	37-48	apolipoprotein A-I	Mus musculus	66-72	
18540024-3	2008	Our goal in this study was to determine whether Hcy could interfere with the ability of simvastatin to increase ApoA-I synthesis or to modify statin-dependent regulation of inflammatory factors.	Simvastatin	88-99	apolipoprotein A-I	Mus musculus	112-118	
18224302-0	2008	Simvastatin reverses the hypertension of heterozygous mice lacking cystathionine beta-synthase and apolipoprotein A-I.	Simvastatin	0-11	apolipoprotein A-I	Mus musculus	99-117	
18224302-9	2008	In conclusion, the results of this study demonstrate that the use of simvastatin can improve blood pressure control in mice with elevated homocysteinemia and low levels of apoA-I, and this effect is mediated by mechanisms independent of plasma lipids and related to nitric oxide levels.	Simvastatin	69-80	apolipoprotein A-I	Mus musculus	172-178	
28242047-5	2017	METHODS: Hypocholesterolemic apolipoprotein A1 (apoA1) knockout mice were administered high dose simvastatin twice daily for 3 days.	Simvastatin	97-108	apolipoprotein A-I	Mus musculus	29-46	
28242047-5	2017	METHODS: Hypocholesterolemic apolipoprotein A1 (apoA1) knockout mice were administered high dose simvastatin twice daily for 3 days.	Simvastatin	97-108	apolipoprotein A-I	Mus musculus	48-53